The U.S. Food and Drug Administration (FDA) has qualified the OsiriX CDE Software Module through the Medical Device Development Tools (MDDT) program
FDA Qualifies First Biomarker Test as Part of Medical Device Development Tools (MDDT) Program
More from Medical Device Development Tools (MDDT) ProgramMore posts in Medical Device Development Tools (MDDT) Program »
More from United States Food and Drug Administration - US FDAMore posts in United States Food and Drug Administration - US FDA »
- EU – Team-NB Position Paper on Documentation Requirements for Drug Device Combination Products Falling in the Scope of Article 117 of MDR 2017/745.
- US – FDA Issues Immediately in Effect Guidance on Ventilators During COVID-19
- US – Ventilator Supply Mitigation Strategies – Letter to Health Care Providers
- US – Update on the Ethylene Oxide Sterilization Master File Pilot Program
- US – FDA Engagement to Mitigate Potential Shortage of Personal Protective Equipment (PPE)
Be First to Comment